Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry

被引:34
作者
Greene, Stephen J. [1 ,2 ]
Ezekowitz, Justin A. [3 ]
Anstrom, Kevin J. [1 ]
Demyanenko, Vladimir [1 ]
Givertz, Michael M. [4 ,5 ]
Pina, Ileana L. [6 ]
O'connor, Christopher M. [7 ]
Koglin, Joerg [8 ]
Roessig, Lothar [9 ]
Hernandez, Adrian F. [1 ,2 ]
Armstrong, Paul W. [3 ]
Mentz, Robert J. [1 ,2 ]
机构
[1] Duke Clin Res Inst, 300 West Morgan St, Durham, NC 27701 USA
[2] Duke Univ, Div Cardiol, Sch Med, Durham, NC USA
[3] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada
[4] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA
[5] Harvard Med Sch, Boston, MA 02115 USA
[6] Jefferson Univ, Dept Med, Philadelphia, PA USA
[7] Inova Heart & Vasc Inst, Falls Church, VA USA
[8] Merck, Kenilworth, NJ USA
[9] Bayer AG, Wuppertal, Germany
关键词
Heart failure; reduced ejection fraction; registry; medication; dosage; MANAGEMENT; INITIATION; GUIDELINE; ADHERENCE;
D O I
10.1016/j.cardfail.2022.02.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: For patients hospitalized for heart failure with reduced ejection fraction (HFrEF), guidelines recommend optimization of medical therapy prior to discharge. The degree to which changes in medical therapy occur during hospitalizations for HFrEF in North American clinical practice is unclear. Methods: The VICTORIA registry (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) enrolled patients hospitalized for worsening chronic HFrEF across 51 sites in the United States and Canada from February 2018-January 2019. In patients with complete medication data who were not receiving dialysis, use and dose of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), angiotensin receptor neprilysin inhibitor (ARNI), beta-blocker, mineralocorticoid receptor antagonist (MRA), and sodium glucose cotransporter-2 inhibitors (SGLT2i) were assessed at admission and discharge. Results: Of 1695 patients, the median (IQR) age was 69 (59-79) years, and 33% were women. Among eligible patients, 33%, 25% and 55% were not prescribed ACEI/ARB/ARNI, betablocker, and MRA at discharge, respectively; 99% were not prescribed SGLT2i. For each medication, > 50% of patients remained on stable subtarget doses or no medication during hospitalization. In-hospital rates of initiation/dose increase were 20% for ACEI/ARB, 4% for ARNI, 20% for beta-blocker, 22% for MRA, and < 1% for SGLT2i; corresponding rates of dose decrease/discontinuation were 11%, 2%, 9%, 5%, and < 1%, respectively. Overall, 17% and 28% of eligible patients were prescribed triple therapy prior to admission and at discharge, respectively. At both admission and discharge, 1% of patients were prescribed triple therapy at target doses. Across classes of medication, multiple factors were independently associated with higher likelihood of in-hospital initiation/dosing increase (eg, Canadian enrollment, white race, admission to intensive care units) and discontinuation/dosing decrease (eg, worse renal function, admission to intensive care units). Conclusions: In this contemporary North American registry of patients hospitalized for worsening chronic HFrEF, for each recommended medical therapy, the large majority of eligible patients remained on stable subtarget doses or without medication at admission and discharge. Although most patients had no alterations in medical therapy, hospitalization in Canada and multiple patient characteristics were associated with higher likelihood of favorable in-hospital medication changes.
引用
收藏
页码:1063 / 1077
页数:15
相关论文
共 50 条
  • [41] Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction
    Abraham, William T.
    Zile, Michael R.
    Weaver, Fred A.
    Butter, Christian
    Ducharme, Anique
    Halbach, Marcel
    Klug, Didier
    Lovett, Eric G.
    Mueller-Ehmsen, Jochen
    Schafer, Jill E.
    Senni, Michele
    Swarup, Vijay
    Wachter, Rolf
    Little, William C.
    JACC-HEART FAILURE, 2015, 3 (06) : 487 - 496
  • [42] Devices for Autonomic Regulation Therapy in Heart Failure With Reduced Ejection Fraction
    Wagner, Benjamin R.
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2018, 26 (01) : 43 - 49
  • [43] Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction
    Ruddy, Jean M.
    Kroman, Anne
    Baicu, Catalin F.
    Zile, Michael R.
    HEART FAILURE CLINICS, 2024, 20 (01) : 39 - 50
  • [44] Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction
    Straw, Sam
    McGinlay, Melanie
    Witte, Klaus K.
    OPEN HEART, 2021, 8 (01):
  • [45] Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction
    Stolfo, Davide
    Sinagra, Gianfranco
    Savarese, Gianluigi
    CARDIAC FAILURE REVIEW, 2022, 8
  • [46] Evaluation of potential underuse of cardiac resynchronization therapy for heart failure with reduced ejection fraction
    Takano, Makoto
    Nakayama, Yui
    Matsuda, Hisao
    Harada, Tomoo
    Akashi, Yoshihiro J.
    JOURNAL OF ARRHYTHMIA, 2021, 37 (06) : 1532 - 1536
  • [47] Improving Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: A Review of Implementation Strategies
    Harrington, Josephine
    Rao, Vishal N.
    Leyva, Monica
    Oakes, Megan
    Mentz, Robert J.
    Bosworth, Hayden B.
    Pagidipati, Neha J.
    JOURNAL OF CARDIAC FAILURE, 2024, 30 (02) : 376 - 390
  • [48] Heart failure with preserved ejection fraction: A precursor of heart failure with reduced ejection fraction or a distinct syndrome?
    Miani, Daniela
    Badano, Luigi P.
    De Biaggio, Paola
    Albanese, Maria Cecilia
    Ghidina, Marco
    Proclemer, Alessandro
    Fioretti, Paolo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 149 (01) : 139 - 140
  • [49] Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation
    Ahn, Min-Soo
    Yoo, Byung-Su
    Son, Jung-Woo
    Park, Young Jun
    Lee, Hae-Young
    Jeon, Eun-Seok
    Kang, Seok-Min
    Choi, Dong-Ju
    Kim, Kye Hun
    Cho, Myeong-Chan
    Kim, Seong Yoon
    Kang, Dae Ryong
    Go, Tae-Hwa
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (40) : 1 - 13
  • [50] Heart Failure Without a Reduced Ejection Fraction
    Kumar, Sant
    Psotka, Mitchell A.
    AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (10) : S187 - S194